Dr. Chris Roberts AO
Non-Executive Director, Member of the Risk Management and Audit Committee
B.Eng (Honours), MBA, PhD
Dr. Roberts has more than 40 years’ experience in the medical device industry, including as the former CEO of Cochlear Limited (ASX:COH) from 2004 to 2015, Executive Vice President of ResMed Inc (NYSE:RMD) from 1992 to 2003 and as a Director until November 2017. He is currently a Non-Executive Director of: HealthCo Healthcare and Wellness REIT (ASX: HCW), HMC Capital Partners Fund 1, Clarity Pharmaceuticals Limited (ASX:CU6), Nutromics Pty Ltd, Atmo Biosciences Limited and the Cochlear Foundation Board. He is also a Governor of the Centenary Institute Cancer Medicine and Cell Biology.
Dr. Roberts has been nominated by HMC Capital Partners Fund 1, a ~19% shareholder in Sigma.